These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 16914086

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs.
    Vallette-Kasic S, Figarella-Branger D, Grino M, Pulichino AM, Dufour H, Grisoli F, Enjalbert A, Drouin J, Brue T.
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3050-6. PubMed ID: 12843142
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance.
    Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY.
    Oncogene; 1994 Apr; 9(4):1021-7. PubMed ID: 8134105
    [Abstract] [Full Text] [Related]

  • 6. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin.
    Yaswen L, Diehl N, Brennan MB, Hochgeschwender U.
    Nat Med; 1999 Sep; 5(9):1066-70. PubMed ID: 10470087
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Abnormalities of the hypothalamo-pituitary-thyroid axis in the pro-opiomelanocortin deficient mouse.
    Martin NM, Small CJ, Sajedi A, Liao XH, Weiss RE, Gardiner JV, Ghatei MA, Bloom SR.
    Regul Pept; 2004 Nov 15; 122(3):169-72. PubMed ID: 15491787
    [Abstract] [Full Text] [Related]

  • 9. Genetic modifications of mouse proopiomelanocortin peptide processing.
    Costa JL, Forbes S, Brennan MB, Hochgeschwender U.
    Mol Cell Endocrinol; 2011 Apr 10; 336(1-2):14-22. PubMed ID: 21195130
    [Abstract] [Full Text] [Related]

  • 10. Altered glucose homeostasis in proopiomelanocortin-null mouse mutants lacking central and peripheral melanocortin.
    Hochgeschwender U, Costa JL, Reed P, Bui S, Brennan MB.
    Endocrinology; 2003 Dec 10; 144(12):5194-202. PubMed ID: 12970157
    [Abstract] [Full Text] [Related]

  • 11. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans.
    Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A.
    Nat Genet; 1998 Jun 10; 19(2):155-7. PubMed ID: 9620771
    [Abstract] [Full Text] [Related]

  • 12. Preservation of eumelanin hair pigmentation in proopiomelanocortin-deficient mice on a nonagouti (a/a) genetic background.
    Slominski A, Plonka PM, Pisarchik A, Smart JL, Tolle V, Wortsman J, Low MJ.
    Endocrinology; 2005 Mar 10; 146(3):1245-53. PubMed ID: 15564334
    [Abstract] [Full Text] [Related]

  • 13. In situ hybridization study of pro-opiomelanocortin (POMC) gene expression in human pituitary corticotrophs and their adenomas.
    Stefaneanu L, Kovacs K, Horvath E, Lloyd RV.
    Virchows Arch A Pathol Anat Histopathol; 1991 Mar 10; 419(2):107-13. PubMed ID: 1651583
    [Abstract] [Full Text] [Related]

  • 14. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
    Teshima T, Hara Y, Takekoshi S, Teramoto A, Osamura RY, Tagawa M.
    Domest Anim Endocrinol; 2009 Jan 10; 36(1):3-12. PubMed ID: 18818046
    [Abstract] [Full Text] [Related]

  • 15. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
    Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Vergès B, Chabre O, Calender A, Groupe d'études des Tumeurs Endocrines.
    Am J Surg Pathol; 2008 Apr 10; 32(4):534-43. PubMed ID: 18300794
    [Abstract] [Full Text] [Related]

  • 16. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses.
    Heinrichs M, Baumgärtner W, Capen CC.
    Vet Pathol; 1990 Nov 10; 27(6):419-25. PubMed ID: 2177580
    [Abstract] [Full Text] [Related]

  • 17. Analysis of endocrine active and clinically silent corticotropic adenomas by in situ hybridization.
    Lloyd RV, Fields K, Jin L, Horvath E, Kovacs K.
    Am J Pathol; 1990 Aug 10; 137(2):479-88. PubMed ID: 2167013
    [Abstract] [Full Text] [Related]

  • 18. Altered proopiomelanocortin gene expression in adrenocorticotropin-producing nonpituitary tumors. Comparative studies with corticotropic adenomas and normal pituitaries.
    de Keyzer Y, Bertagna X, Lenne F, Girard F, Luton JP, Kahn A.
    J Clin Invest; 1985 Nov 10; 76(5):1892-8. PubMed ID: 2997296
    [Abstract] [Full Text] [Related]

  • 19. Role of proopiomelanocortin neurons and peptides in the regulation of energy homeostasis.
    Low MJ.
    J Endocrinol Invest; 2004 Nov 10; 27(6 Suppl):95-100. PubMed ID: 15481808
    [Abstract] [Full Text] [Related]

  • 20. Effects of heterozygosity for the Rb-1t19neo allele in the mouse.
    Harrison DJ, Hooper ML, Armstrong JF, Clarke AR.
    Oncogene; 1995 Apr 20; 10(8):1615-20. PubMed ID: 7731716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.